Low-dose Tricyclic Antidepressants for Irritable Bowel Syndrome: Definitive Evidence of Benefit from ATLANTIS
Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in Primary Care (ATLANTIS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial,” by Ford AC, Wright-Hughes A, Alderson S, et al. Lancet 2023; 402: 1773-85.
Evidence-Based GI: An ACG Publication and Podcast
en-usDecember 13, 2023